论文部分内容阅读
目的:探讨黄芪多糖对非小细胞肺癌外周血糖类抗原125(CA125)、血管内皮生长因子(VEGF)及基质金属蛋白酶-9(MMP-9)表达的影响。方法:选取我院收治的非小细胞肺癌患者100例,随机分为两组,每组各50例,对照组予常规放疗,实验组在对照组的基础上,加以注射用黄芪多糖250 mg,溶于500 ml生理盐水中,日1次,与放疗同步,7日为1个疗程,治疗2个疗程。治疗后,观察和比较两组患者的临床疗效,血常规、血CA125、VEGF及MMP-9的表达情况。结果:1治疗后,实验组的总有效率为86.0%,对照组的总有效率为64%,显著低于实验组,差异有统计学意义(P<0.05)。2治疗后,对照组Hb、WBC、NEUT较治疗前均显著降低,而RBC变化不明显,实验组Hb、WBC、NEUT均显著高于对照组,差异均有统计学意义(P<0.05)。3治疗后1、5、14天,两组患者的外周血CA125、VEGF及MMP-9表达均较治疗前有所降低,且实验组治疗后5、14天外周血CA125、VEGF及MMP-9表达均显著低于对照组,差异有统计学意义(P<0.05)。结论:黄芪多糖能够有效降低非小细胞肺癌患者外周血CA125、VEGF及MMP-9表达,提高其临床疗效,改善放疗所致骨髓抑制。
Objective: To investigate the effect of astragalus polysaccharides on the expression of peripheral blood carbohydrate antigen 125 (CA125), vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer. Methods: One hundred patients with non-small cell lung cancer admitted to our hospital were randomly divided into two groups with 50 cases in each group. The control group received conventional radiotherapy. On the basis of the control group, the experimental group was given astragalus polysaccharide 250 mg, Dissolved in 500 ml of normal saline, day 1, synchronized with radiotherapy, on the 7th for a course of treatment, treatment 2 courses. After treatment, the clinical curative effect, blood routine, blood levels of CA125, VEGF and MMP-9 in the two groups were observed and compared. Results: After treatment, the total effective rate was 86.0% in the experimental group and 64% in the control group, which was significantly lower than that in the experimental group (P <0.05). After treatment, the levels of Hb, WBC and NEUT in control group were significantly lower than those before treatment, while the changes of RBC were not obvious. The levels of Hb, WBC and NEUT in experimental group were significantly higher than those in control group (P <0.05). The levels of CA125, VEGF and MMP-9 in the peripheral blood of the two groups were lower than those before the treatment, and the levels of CA125, VEGF and MMP-9 The expression was significantly lower than the control group, the difference was statistically significant (P <0.05). Conclusion: Astragalus polysaccharide can effectively reduce the expression of CA125, VEGF and MMP-9 in peripheral blood of patients with non-small cell lung cancer, improve its clinical curative effect and improve the bone marrow suppression induced by radiotherapy.